Dr Reddys Laboratories (RDY) Notes Payables (2009 - 2026)

Dr Reddys Laboratories has reported Notes Payables for 15 years, with the latest figure at $53.3 million in Q2 2026.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $53.3 million in Q2 2026; TTM through Jun 2026 was $53.3 million, a N/A change from a year earlier, with the FY2026 full-year figure at $630.0 million, up 41.57% from the prior year.
• Notes Payables was $53.3 million for Q2 2026 at Dr Reddys Laboratories, down from $75.5 million in the prior quarter.
• The five-year high for Notes Payables was $439.3 million in Q1 2025, with the low at $37628.3 in Q3 2022.
• Average Notes Payables over 5 years is $97.7 million, with a median of $47.6 million recorded in 2022.
• The largest YoY upside for Notes Payables was 291688.21% in 2022 against a maximum downside of 99.38% in 2022.
• Over 5 years, Notes Payables stood at $14.5 million in 2022, then plunged by 99.67% to $48387.9 in 2023, then jumped by 1010.35% to $537273.3 in 2024, then surged by 6479.59% to $35.4 million in 2025, then surged by 50.84% to $53.3 million in 2026.
• The last three Notes Payables figures came in at $53.3 million (Q2 2026), $75.5 million (Q1 2026), and $35.4 million (Q4 2025), per Business Quant data.